Diagnostic and Interventional Cardiology has been recognized as a finalist in the Jesse H. Neal Awards for the third year in a row. DAIC editor Dave Fornell was named a finalist in the Best Range of Work by a Single Author category for his reporting from the Transcatheter Cardiovascular Therapeutics (TCT) 2018 conference, that included blog posts and video coverage.
GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE Chairman and CEO Larry Culp Jr. said the deal signified that a planned 2019 initial public offering (IPO) for GE Healthcare is now unlikely. GE is reportedly weighing its options following the deal, which casts off the biopharmaceutical business for $21.4 billion.
Here is what I thought were the top five most important take-away presentations from the 2019 Society of Thoracic ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Philips will unveil a new mixed reality concept developed together with Microsoft that the company says is designed for the operating room of the future. Based on Philips’ Azurion image-guided therapy platform and Microsoft’s HoloLens 2 holographic computing platform, the companies will showcase novel augmented reality applications for image-guided minimally invasive therapies. The technology will debut at Mobile World Congress (MWC) Barcelona, Feb. 25-28 in Barcelona, Spain.
The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions in Las Vegas, May 19-22 ...
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
At the recent Healthcare Information and Management Systems Society (HIMSS) annual conference, AT&T’s healthcare team demonstrated the key role connectivity and the internet of medical things (IoMT) plays throughout the continuum of care. This concept was highlighted by a demonstration of the Bodyport remote monitoring solution.
Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The device was approved to facilitate, guide and support a guidewire while accessing the coronary system, the exchange of guidewires, and injection of radiopaque contrast media or saline solutions.
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the increased risk of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Medtronic is recalling its dual chamber implantable pulse generators (IPGs) due to the possibility of a software error that can result in a lack of pacing. Patients and physicians cannot predict whether and when this software error might occur. A lack of pacing could result in patients experiencing slow heart beating, low blood pressure, and symptoms such as light headedness, fainting and even death.
Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based ...
California-based Vascular Dynamics Inc. (VDI) is sponsoring a new clinical trial, called CALM-2 (Controlling And Lowering blood pressure with MobiusHD), of a novel endovascular approach to treat patients with drug-resistant hypertension. St. Bartholomew’s Hospital in London is helping to lead efforts in the U.K. as a key study site.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Ochsner Health System in Louisiana recently announced a new partnership with device data management and remote monitoring vendor Geneva Health Solutions (GHS) for implantable cardiac devices. This partnership marks the first time the GHS cloud-based technology platform and remote monitoring service for patients with cardiac implants will be utilized in the region, which includes Louisiana, Arkansas, Mississippi, Alabama and Georgia. The GHS system will drive full automated scheduling and reporting in collaboration with Ochsner’s established Epic electronic medical record (EMR).
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published in Science Translational Medicine.
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular events, including strokes, heart attacks and blood clots, according to a study published in the American Heart Association’s journal Circulation.